Ventripoint Diagnostics Ltd.
TSX VENTURE : VPT

Ventripoint Diagnostics Ltd.

April 15, 2014 08:48 ET

Montefiore Hospital in New York City to Conduct Cardiac Re-Admission Study Using the Ventripoint VMS™ Heart Analysis System

SEATTLE, WASHINGTON--(Marketwired - April 15, 2014) - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) announces that the Montefiore-Einstein Center for Heart and Vascular Care in the Bronx, New York City has received approval to conduct a re-admission study in patients with heart failure to determine if the quantitative assessment of right-heart function using the Ventripoint VMS™ Heart Analysis System would enable cardiologists to identify those patients most likely to return and be re-admitted within 30 days. Dr. Mario Garcia and Dr. Ileana Piña are leading the study.

"We are pleased to initiate this study to look for better ways to assess right heart function. The VMS™ is a simple rapid technique, which uses conventional 2D echocardiographic data to obtain accurate functional information and should be prognostic in this patient population," stated Dr. Garcia, Chief of Cardiology at Montefiore.

The average cardiac re-admission rate within 30 days in the United States is 26%. It is estimated that 48% of people with heart failure have significant right-heart involvement. Routinely, the right heart is subjectively assessed with echocardiography but reliable functional information is not obtained.

"We are facing a new paradigm in healthcare today," says Dr. Piña, "We see an explosion of risk factors for heart disease, coupled with a demand to practice evidence-based medicine and to lower costs."

This re-admission rate puts an extra burden on the healthcare system and the Affordable Care Act uses the re-admission rate to penalize hospital by clawing back 1-3% of total billings for those hospitals with higher than acceptable re-admission rates. Last year, U.S. hospitals lost $225 million in re-imbursements due to unacceptably high re-admission rates.

"We will immediately install two VMS™ heart analysis systems at Montefiore Hospital and begin recruitment," stated Dr. George Adams, CEO of Ventripoint. "We would expect to have interim data midsummer and will initiate additional clinical sites based upon this information."

The VMS™ is approved for clinical use for selected indications in Canada, Europe and the United States.

About Montefiore Hospital

Montefiore Medical Center is a 1,418-bed general medical and surgical facility in the Bronx, New York. It ranked among the top hospitals nationally in Cardiology and Heart Surgery, Diabetes and Endocrinology, and Neurology and Neurosurgery in U.S. News & World Report's "America's Best Hospitals" 2013-2014 survey. Through its enduring partnership with Albert Einstein College of Medicine, it combines clinical care with research to deliver the most current treatments available.

About Dr. Mario Garcia

Mario Garcia, MD, is Chief of the Division of Cardiology and Co-Director, of the Montefiore Einstein Center for Heart and Vascular Care. Dr. Garcia is an internationally known leader in the development and clinical advancement of cardiac diagnostic technology, including cardiac CT, echocardiography and cardiac magnetic resonance imaging. Dr. Garcia is board-certified in cardiovascular medicine, internal medicine and echocardiography.

About Dr. Ileana Piña

Ileana Piña, MD, MPH, is a nationally renowned cardiologist known for her work in heart failure and development of multidisciplinary clinical interventions to improve patient rehabilitation outcomes. Dr. Piña serves as advisor/consultant to the FDA's Center for Devices and Radiological Health and their section of Epidemiology. She is also consultant to Novartis Pharmaceuticals and GE HealthCare. She is the author/co-author of over 100 publications in print, and a world-renowned speaker on heart failure management. Dr. Piña was on the writing committee of the new American Heart Association Guidelines for the Prevention of Heart Disease.

About Ventripoint Diagnostics Ltd.

Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate tool for measuring right ventricle heart function. The Corporation has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts -- a multi-billion dollar market potential.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Company's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Company undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Contact Information